Eli Lilly plans to invest over $3.5 billion in a new manufacturing plant in Pennsylvania's Lehigh Valley to produce next-generation obesity drugs, including the promising retatrutide, as part of a larger strategy to enhance domestic manufacturing.
Data sourced from public RSS feeds and News APIs.
